Global Panic Disorders Market Size, Share, Growth, Trends, and Forecast, 2032

What is the projected value for the panic disorder market during 2024 to 2032?

The global Panic Disorders market size accrued earnings worth approximately USD 9.87 Billion in 2023 and is predicted to gain revenue of about USD 14.18 Billion by 2032, is set to record a CAGR of nearly 4.10% over the period from 2024 to 2032.

Request Free Sample

When a patient suffers from frequent sudden panic attacks, then that patient is suffering from panic disorder, which is a type of anxiety disorder. The patient has the following symptoms when panic attacks occur such as intense fear, sweating, shortness of breath, palpitations, shaking, numbness, etc. The reason or the cause for the panic attack is anonymous.

Global Panic Disorders Market: Growth Factors

The increasing awareness regarding the disorders, the growing prevalence of mental and anxiety disorders, and the availability of treatment options that are effective are some of the key factors that estimate to fuel the growth of the global panic disorders market. The increasing initiatives that are being taken by the leading players in order to create an understanding among the consumers will accelerate the growth of the market. In recent years, several drugs are in different phases of clinical trials, which will be commercialized soon thus encouraging the growth of the market. On the other hand, in underdeveloped and developing economies there is a lack of awareness regarding the severity of these disorders if not treated is the major factor that is likely to restrict the overall growth of the market in the coming years.

Request Free Sample

Panic Disorders Market: Report Scope

Global Panic Disorders Market: Segmentation

The panic disorder market is globally segmented into its type, drug class, and regions.

Based on type, the global market is segregated into agoraphobia, social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), bipolar disorder, post-traumatic stress disorder (PTSD), specific phobias, generalized anxiety disorder (GAD), major depressive disorder.

Based on the drug class, the market is categorized into selective serotonin reuptake inhibitors (SSRI), benzodiazepines (BZD), and serotonin-norepinephrine reuptake inhibitors (SNRI). The selective serotonin reuptake inhibitor (SSRI) is further sub-segmented into paroxetine (Paxil, Pexeva), fluoxetine (Prozac), and sertraline (Zoloft).

Global Panic Disorders Market: Regional Analysis

North America predicts to lead the global panic disorders market and hold a huge share of the global market. The high growth in this region can be attributed to the factors such as the presence of a large number of players that are involved in this field and the increasing awareness among consumers regarding the accessibility of therapeutics that are effective for panic disorders. Europe expects to remain in the second position. Asia Pacific projects witnessing robust growth in the coming years, owing to the unexploited lucrative opportunities for the key players. In addition, the expanding purchasing capacity of the consumers in the region expects to encourage the growth of the market. India and China anticipate contributing considerably towards the growth of the panic disorders market in the Asia Pacific region.

Global Panic Disorders Market: Competitive Players

Some of the key market players that are involved in the panic disorders market include

• Bristol-Myers Squibb Company
• Boehringer Ingelheim GmbH.
• GlaxoSmithKline Plc.
• F. Hoffmann-La Roche Ltd.
• Valeant Pharmaceuticals International, Inc.
• Pfizer, Inc.
• H. Lundbeck A/S
• Actavis Plc.
• Sanofi
• Eli Lilly and Company
• Neurocrine Biosciences, Inc.
• Mylan, Inc.
• and AstraZeneca Plc.

The report segments the global panic disorder market as follows:

By Type 

• Agoraphobia
• Social anxiety disorder (SAD)
• Obsessive-compulsive disorder (OCD)
• Bipolar disorder
• Post-traumatic stress disorder (PTSD)
• Specific phobias
• Generalized anxiety disorder (GAD)
• Major depressive disorder

By Drug Class 

• Selective serotonin reuptake inhibitor (SSRI)
• Benzodiazepines (BZD)
• Serotonin-norepinephrine reuptake inhibitor (SNRI)
  • Paroxetine
  • Fluoxetine  
  • Sertraline

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America